Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Dynavax Technologies in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. White anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $31.00 price target on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies' Q4 2025 earnings at $0.09 EPS and FY2027 earnings at $0.64 EPS.
Separately, StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday.
Read Our Latest Research Report on Dynavax Technologies
Dynavax Technologies Price Performance
Shares of NASDAQ DVAX traded up $0.06 during trading on Friday, reaching $12.45. The company had a trading volume of 1,252,149 shares, compared to its average volume of 1,916,977. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.30. The stock has a 50-day moving average price of $12.76 and a two-hundred day moving average price of $11.67. The stock has a market capitalization of $1.64 billion, a PE ratio of 95.78 and a beta of 1.34.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. State of New Jersey Common Pension Fund D acquired a new stake in shares of Dynavax Technologies during the second quarter worth $1,811,000. Renaissance Technologies LLC boosted its stake in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock worth $27,830,000 after buying an additional 53,600 shares during the last quarter. XTX Topco Ltd purchased a new stake in Dynavax Technologies in the 2nd quarter valued at about $184,000. Evoke Wealth LLC acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at about $305,000. Finally, Public Sector Pension Investment Board increased its stake in shares of Dynavax Technologies by 8.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 287,958 shares of the biopharmaceutical company's stock valued at $3,234,000 after acquiring an additional 23,012 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
